GenOway Closes 2025 with a Revenue of 21 Million Euros, Down by 5%

Financial Performance in 2025

GenOway recorded a consolidated revenue of 21.0 million euros for the fiscal year 2025, which ended on December 31, showing a decline of 5% compared to 22.1 million euros in 2024. This decrease occurred in a generally cautious economic environment, according to the company. The year 2025 was characterized by the deployment of a strategic roadmap that included a complete overhaul of the commercial organization and the implementation of a new marketing plan. In the first half of 2025, the activity fell by 10% to 9.6 million euros, with the effects of this commercial transformation, including recruitments and the new structure, impacting the results. However, the second half of 2025 stabilized at 11.4 million euros, the same level as the second half of 2024, thanks to the launch of new preclinical research models in immuno-oncology and immuno-inflammation, as well as the strengthening of commercial and marketing resources. GenOway confirms the maintenance of a solid level of profitability throughout the year, in line with the commitments of its strategic plan ROUTE 50+, with an EBITDA margin above 15%. In the first half of 2025, this EBITDA margin reached 16.9%. The cost-saving and productivity improvement plans implemented in 2025 aimed at 0.8 million euros in savings for that year, complemented by an additional 1.4 million euros expected in 2026.

Strategic Developments and Future Outlook

At the end of 2025, GenOway expanded its strategic plan, now named ROUTE50 +DATA, following the acquisition of certain assets from a leading platform in OMICS and data science from BIOASTER, a research institute founded by industrialists Sanofi, Biomérieux, and BPI in partnership with public research. The acquisition of these assets was financed through a private placement of 7 million euros carried out in December 2025. This operation allows GenOway to gain about a year on its roadmap and will enable it to have, by the end of the first quarter of 2026, a technological platform (skills, equipment, and premises) at the level initially planned for the end of 2026. The new activity in the field of predictive data is expected to generate initial revenues in 2026, particularly within precompetitive consortia built with pharmaceutical partners. A positive contribution from these activities to GenOway's profitability is expected from 2027. For 2026, the company aims for an organic growth exceeding 10%, resulting in a revenue of more than 23 million euros. In the longer term, GenOway confirms the initial objectives of the ROUTE 50+ plan: to achieve a revenue of 50 million euros by 2028, accompanied by an EBITDA margin above 15%, including the necessary investments for its realization. These objectives are intended to be updated during the 2026 fiscal year to integrate additional revenues and profitability from the acquisition of the OMICS and data science assets.

Anticipations for a Dynamic 2026

GenOway anticipates a dynamic 2026 supported by the commercial transformation implemented in 2025, with a doubling of the commercial staff and a new marketing plan aimed at enhancing the company's reputation. The launch of two new ranges of Catalog models, in inflammation and safety, is planned for 2026, currently in the validation phase. The ramp-up of international development will also be a key focus, particularly in China where the joint venture GenOway Shanghai aims to double its revenue in 2026 compared to 2025, before targeting between 5 and 10 million euros in revenue by 2028. Several other distributors in Asia and certain Western markets will be announced in 2026. GenOway also announces the arrival of Marie-Laure Warlouzet as the new Chief Administrative and Financial Officer, succeeding Benjamin Bruneau. Marie-Laure Warlouzet has 20 years of experience in financial management positions within international groups, with a focus on value creation and business transformation.